Polyplus, a France-based drug manufacturer, provides innovative upstream technologies for cell and gene therapies. These include transfection as well as other high-quality GMP grade DNA/RNA delivery reagents and plasmid DNA.
Acknowledging its significant growth rate, Polyplus is expected to generate sales revenue in the upper double-digit million dollar range and is a very substantial EBITDA margin in 2023.
The company has been expanding its focus beyond transfection reagents through acquisitions in adjacent technologies like plasmid design, and protein and plasmid manufacturing, broadening its upstream portfolio for gene therapies as well as gene-modified cell therapies.
“The innovative solutions of Polyplus are highly complementary to our portfolio, in particular to our offering of cell culture media and critical components for the development and manufacture of advanced therapies, and there are also strong synergies with our portfolio of downstream solutions for the manufacture of gene therapeutics,” said René Fáber, member of the Executive Board and Head of the Bioprocess Solutions division of Sartorius.
Founded in 2001, Polyplus is based in Strasbourg, France, and has locations in France, Belgium, the U.S., and China.
Polyplus’ transfection reagents and plasmids are critical components in manufacturing viral vectors used in cell and gene therapies and other advanced medicinal therapeutic products.
“As a leading supplier of critical components to produce cell and gene therapies, Sartorius and Polyplus together will be excellently positioned to play a significant role in this dynamic field,” adds Fáber.
“We would be excited to join forces with a world-class bioprocess market leader as Sartorius. Our combined portfolios would create a unique ability to optimize the total process workflow to deliver unparalleled value for cell/gene and DNA/RNA therapy customers, in a strong effort to make these critical needed therapies more affordable,” said Mario Philips, CEO of Polyplus.
Sartorius AG will receive a bridge loan facility from J.P. Morgan for a transitional period to finance the transaction. Sartorius intends to refinance this loan with long-term financing instruments which might also include an equity component.
Lee Buckler, SVP Advanced Therapies, Blood Centers of America, Advanced Therapies Network, reflects on two decades of working within the advanced therapies industry as Phacilitate celebrates 20 years of operating in the field.